FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310397725> ?p ?o ?g. }

• W4310397725 abstract "Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology. Currently, pirfenidone and nintedanib are the only FDA-approved drugs for the treatment of IPF and are now the standard of care. This is a significant step in slowing down the progression of the disease. However, the drugs are unable to stop or reverse established fibrosis. Several retrospective clinical studies indicate that proton pump inhibitors (PPIs; FDA-approved to treat gastroesophageal reflux) are associated with favorable outcomes in patients with IPF, and emerging preclinical studies report that PPIs possess antifibrotic activity. In this study, we evaluated the antifibrotic efficacy of the PPI esomeprazole when combined with pirfenidone in vitro and in vivo. In cell culture studies of IPF lung fibroblasts, we assessed the effect of the combination on several fibrosis-related biological processes including TGFβ-induced cell proliferation, cell migration, cell contraction, and collagen production. In an in vivo study, we used mouse model of TGFβ-induced lung fibrosis to evaluate the antifibrotic efficacy of esomeprazole/pirfenidone combination. We also performed computational studies to understand the molecular mechanisms by which esomeprazole and/or pirfenidone regulate lung fibrosis. We found that esomeprazole significantly enhanced the anti-proliferative effect of pirfenidone and favorably modulated TGFβ-induced cell migration and contraction of collagen gels. We also found that the combination significantly suppressed collagen production in response to TGFβ in comparison to pirfenidone monotherapy. In addition, our animal study demonstrated that the combination therapy effectively inhibited the differentiation of lung fibroblasts into alpha smooth muscle actin (αSMA)-expressing myofibroblasts to attenuate the progression of lung fibrosis. Finally, our bioinformatics study of cells treated with esomeprazole or pirfenidone revealed that the drugs target several extracellular matrix (ECM) related pathways with esomeprazole preferentially targeting collagen family members while pirfenidone targets the keratins. In conclusion, our cell biological, computational, and in vivo studies show that the PPI esomeprazole enhances the antifibrotic efficacy of pirfenidone through complementary molecular mechanisms. This data supports the initiation of prospective clinical studies aimed at repurposing PPIs for the treatment of IPF and other fibrotic lung diseases where pirfenidone is prescribed." @default.
• W4310397725 created "2022-12-10" @default.
• W4310397725 creator A5012082101 @default.
• W4310397725 creator A5015016762 @default.
• W4310397725 creator A5015102287 @default.
• W4310397725 creator A5021656163 @default.
• W4310397725 creator A5048885679 @default.
• W4310397725 creator A5053721033 @default.
• W4310397725 creator A5061689835 @default.
• W4310397725 creator A5063417154 @default.
• W4310397725 creator A5064815115 @default.
• W4310397725 date "2022-11-30" @default.
• W4310397725 modified "2023-10-14" @default.
• W4310397725 title "Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis" @default.
• W4310397725 cites W1513452394 @default.
• W4310397725 cites W1578396116 @default.
• W4310397725 cites W1984645774 @default.
• W4310397725 cites W1985410214 @default.
• W4310397725 cites W1993559550 @default.
• W4310397725 cites W2011100333 @default.
• W4310397725 cites W2015683287 @default.
• W4310397725 cites W2025605750 @default.
• W4310397725 cites W2037501291 @default.
• W4310397725 cites W2037698492 @default.
• W4310397725 cites W2044788332 @default.
• W4310397725 cites W2045686994 @default.
• W4310397725 cites W2050197847 @default.
• W4310397725 cites W2056163657 @default.
• W4310397725 cites W2064517127 @default.
• W4310397725 cites W2067473107 @default.
• W4310397725 cites W2070318597 @default.
• W4310397725 cites W2087373364 @default.
• W4310397725 cites W2098530232 @default.
• W4310397725 cites W2099722910 @default.
• W4310397725 cites W2102974167 @default.
• W4310397725 cites W2121604817 @default.
• W4310397725 cites W2123700925 @default.
• W4310397725 cites W2124649657 @default.
• W4310397725 cites W2129514617 @default.
• W4310397725 cites W2131492414 @default.
• W4310397725 cites W2138871107 @default.
• W4310397725 cites W2144469870 @default.
• W4310397725 cites W2147199669 @default.
• W4310397725 cites W2153423299 @default.
• W4310397725 cites W2159675211 @default.
• W4310397725 cites W2162376488 @default.
• W4310397725 cites W2168666423 @default.
• W4310397725 cites W2292284343 @default.
• W4310397725 cites W2335121178 @default.
• W4310397725 cites W2345117801 @default.
• W4310397725 cites W2523522924 @default.
• W4310397725 cites W2581288636 @default.
• W4310397725 cites W2607145250 @default.
• W4310397725 cites W2612467560 @default.
• W4310397725 cites W2626201505 @default.
• W4310397725 cites W2739715566 @default.
• W4310397725 cites W2795547005 @default.
• W4310397725 cites W2997934774 @default.
• W4310397725 cites W3040876684 @default.
• W4310397725 cites W3041062936 @default.
• W4310397725 cites W3163603143 @default.
• W4310397725 cites W4206462372 @default.
• W4310397725 doi "https://doi.org/10.1038/s41598-022-24985-x" @default.
• W4310397725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36450789" @default.
• W4310397725 hasPublicationYear "2022" @default.
• W4310397725 type Work @default.
• W4310397725 citedByCount "1" @default.
• W4310397725 countsByYear W43103977252023 @default.
• W4310397725 crossrefType "journal-article" @default.
• W4310397725 hasAuthorship W4310397725A5012082101 @default.
• W4310397725 hasAuthorship W4310397725A5015016762 @default.
• W4310397725 hasAuthorship W4310397725A5015102287 @default.
• W4310397725 hasAuthorship W4310397725A5021656163 @default.
• W4310397725 hasAuthorship W4310397725A5048885679 @default.
• W4310397725 hasAuthorship W4310397725A5053721033 @default.
• W4310397725 hasAuthorship W4310397725A5061689835 @default.
• W4310397725 hasAuthorship W4310397725A5063417154 @default.
• W4310397725 hasAuthorship W4310397725A5064815115 @default.
• W4310397725 hasBestOaLocation W43103977251 @default.
• W4310397725 hasConcept C126322002 @default.
• W4310397725 hasConcept C150903083 @default.
• W4310397725 hasConcept C207001950 @default.
• W4310397725 hasConcept C2777714996 @default.
• W4310397725 hasConcept C2778204628 @default.
• W4310397725 hasConcept C2778341716 @default.
• W4310397725 hasConcept C2779832356 @default.
• W4310397725 hasConcept C2780171596 @default.
• W4310397725 hasConcept C2780559512 @default.
• W4310397725 hasConcept C2781244666 @default.
• W4310397725 hasConcept C502942594 @default.
• W4310397725 hasConcept C71924100 @default.
• W4310397725 hasConcept C86803240 @default.
• W4310397725 hasConcept C98274493 @default.
• W4310397725 hasConceptScore W4310397725C126322002 @default.
• W4310397725 hasConceptScore W4310397725C150903083 @default.
• W4310397725 hasConceptScore W4310397725C207001950 @default.
• W4310397725 hasConceptScore W4310397725C2777714996 @default.
• W4310397725 hasConceptScore W4310397725C2778204628 @default.
• W4310397725 hasConceptScore W4310397725C2778341716 @default.
• W4310397725 hasConceptScore W4310397725C2779832356 @default.

• next